Search WHWK
Whitehawk Therapeutics, Inc.
Nasdaq · CIK 1422142
Last close3.7
Daily change-0.06 (-1.60%)
10 Years gain-94.52%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
WHWK · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
28.9Momentum
n/aAcceleration
0.0Confidence
68.0Annual Revenue8
Quarterly Revenue25
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 107.5656%.
ROIC declining · MEDIUMROIC declined by 40.3542 percentage points.
Key Metrics
Revenue Growth TTM-100%OK
Revenue CAGR 3Y-22.27%OK
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-86.73%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y107.57%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $7.15M | $6.39M | -$114.40M | -$97.43M | -$97.99M | 89.36% | -1,601.12% | -1,371.38% | n/a | 61.89M |
| 2025 FY Dec 31, 2024 | $25.98M | $22.96M | -$67.46M | -$59.55M | -$61.20M | 88.36% | -259.62% | -235.55% | -6,699.16% | 27.03M |
| 2024 FY Dec 31, 2023 | $24.35M | $21.55M | -$71.93M | -$59.66M | -$63.64M | 88.47% | -295.36% | -261.29% | n/a | 26.92M |
| 2023 FY Dec 31, 2022 | $15.22M | $13.88M | -$62.68M | -$49.64M | -$50.08M | 91.23% | -411.94% | -329.15% | n/a | 22.51M |
| 2022 FY Dec 31, 2021 | n/a | -$73.04M | -$111.22M | -$22.42M | -$22.47M | n/a | n/a | n/a | n/a | 8.92M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $0.00 | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-337933, 0001193125-25-268895 |
| Revenue Growth TTM | -100% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-337933, 0001193125-25-268895 |
| Revenue CAGR 3Y | -22.27% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-104158 |
| Revenue CAGR 5Y | -12.59% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-104158 |
| Gross Profit CAGR 3Y | -22.81% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-104158 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-337933, 0001193125-25-268895 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| ROIC | -86.73% | NOPAT / Average Invested Capital | OK | 0001193125-26-337933, 0001193125-25-268895 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-337933 |
| Current Ratio | 17.38x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.00 | Revenue / Diluted Shares | OK | 0001193125-26-337933, 0001193125-25-268895 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | 0001193125-26-337933, 0001193125-25-268895 |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001193125-26-104158 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | 0001193125-26-337933 |